MondayMar 13, 2023 9:45 am

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Leverages Top-Tier Leadership and GMP Facility to Advance Rapid Development of New Therapeutic and Prophylactic Technologies for Multiple Diseases and Disorders

BiondVax is a biopharmaceutical company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products, primarily for the treatment of infectious and autoimmune diseases The company is led by CEO Amir Reichman, with over 20 years of international experience as a biopharma expert Amir took company reins in 2021 and pivoted the mission and vision including diversifying risks With new focus and opportunity, BiondVax now developing an innovative alpaca-derived nanosized antibody (“NanoAb”) pipeline BiondVax is aggressively advancing new NanoAb therapeutic and prophylactic technologies owing to exclusive collaborations, previous pharma development experience and a state-of-the-art GMP manufacturing facility Leveraging top-tier pharmaceutical industry…

Continue Reading

FridayMar 10, 2023 11:13 am

Simple Skin Swab Could Help Predict Future Eczema Risks in Kids

Researchers have found that physicians can predict the future risk of eczema in children via simple skin swabs. Their findings show that collecting cells from the top layers of a week-old baby’s skin using sticky strips can allow doctors to predict whether the infant will develop eczema. Atopic dermatitis (AD) is the most common type of eczema. It is characterized by itchy, dry and inflamed skin. While it can occur at any age, the condition is very common in young children. The condition also increases a patient’s risk of developing asthma, hay fever and food allergies. It affects close to…

Continue Reading

ThursdayMar 09, 2023 1:00 pm

Study Documents Dangers of Halting Opioid Treatments for Chronic Pain

An estimated 8% of Americans aged 18 years and older suffer from chronic pain so severe that it limits their day-to-day activities. Epidemiological studies estimate that the overall prevalence of chronic pain among American adults is between 18% and 34.5%. For most of these people, opioids are the most common way to manage their chronic pain enough to engage in daily activities. However, opioids aren’t always effective, and they carry a significant risk of addiction and unwanted side effects. Aside from causing side effects such as nausea, mental fog and constipation, opioids are incredibly addictive, especially for people who take…

Continue Reading

WednesdayMar 08, 2023 1:00 pm

FDA Issues Warning about Reliability of Food Allergy Skin Tests

An estimated 32 million Americans, including around 5.6 million children and 26 million adults, suffer from food allergies. The severity of these food allergies ranges from hives and swelling of the face to difficulty breathing, abdominal pain and diarrhea. Currently one of the most common ways of testing for food allergies is a skin prick test that involves placing a small amount of a certain food on a patient’s skin to see if it will cause an adverse reaction. This method is the most accessible food allergy test, and it usually provides immediate results, allowing patients to discuss means of…

Continue Reading

TuesdayMar 07, 2023 1:10 pm

Study Finds Repeated Head Trauma Increases Brain Cancer Risk

Recent research has revealed that repeated head trauma can elevate the risk of developing brain cancer. The study found that repeated hits to the head can increase risk of a rare and aggressive brain tumor called glioma by more than four times. Brain injuries are the leading cause of disability and death worldwide, and traumatic brain injuries are the number one cause of seizure disorders. University College London Cancer Institute researchers have now determined that head injuries could also increase your risk of brain cancer. The UCL study adds to a growing body of research that has indicated a possible…

Continue Reading

TuesdayMar 07, 2023 10:30 am

India Globalization Capital Inc. (NYSE American: IGC) Focused on Fighting Alzheimer’s Disease with First-of-Kind Treatments in Study Phase

Government showing strong support for bills aimed at treating Alzheimer’s disease IGC’s leading drug candidate recently completed phase 1 of a safety and tolerability trial, and entered phase 2 Company’s proprietary treatments have “the potential to revolutionize the treatment of Alzheimer’s disease” Key legislation designed to fight Alzheimer’s has been introduced in Congress — or actually reintroduced: the NAPA Reauthorization Act was first introduced in the last Congress but is seeing continued support from the current group of elected officials (https://ibn.fm/8vynv). Support for the treatment of Alzheimer’s is essential for organizations such as India Globalization Capital (NYSE American: IGC), a…

Continue Reading

MondayMar 06, 2023 1:26 pm

Climate Change Heightening Risk of Global Infectious Illnesses

The COVID-19 pandemic showed us just how quickly an infectious disease can spread in our modern interconnected world. Just a few months after the disease was first discovered in Wuhan, China, it had spread to most continents and shut down dozens of economies across the world. Even though we are now past the worst of the pandemic, it seems that infectious diseases will keep humanity on its toes for much longer than we thought. A recent analysis has revealed that climate change has significantly increased the world’s risk of infectious diseases. The analysis states that climate change has already upped…

Continue Reading

FridayMar 03, 2023 10:59 am

Study Finds Exposure to Traffic Noise Increases Risk of Tinnitus

While living in urban areas brings plenty of benefits to its residents, it is not always beneficial to their health. For starters, urban dwellers are exposed to a lot more air pollution compared to people living in rural areas. They are also more likely to be infected with communicable diseases due to the dense populations of most cities. And now a recent study has revealed that increased noise levels in urban areas can do more than just annoy residents. The study found that people are more likely to develop tinnitus if they are exposed to traffic noise in their homes.…

Continue Reading

FridayMar 03, 2023 10:30 am

India Globalization Capital Inc. (NYSE American: IGC) Leads the Way Forward with Revolutionary Cannabis-Based Treatment for Alzheimer’s Symptoms

Company’s investigational drug is being tested for the first time ever on humans in an FDA-approved study In phase 1 studies, IGC-AD1 shows potential to safely reduce debilitating symptoms IGC is actively building a portfolio of both cannabis-based and manufactured molecules that can address multiple areas of unmet medical needs In groundbreaking work that establishes its commitment to being a pioneer in the treatment of Alzheimer’s disease, India Globalization Capital (NYSE American: IGC) is developing a cannabis-based investigational drug that is being tested for the first time ever on humans in an FDA-approved study (https://ibn.fm/qsc42). The company is developing its…

Continue Reading

FridayMar 03, 2023 9:00 am

HeartBeam Inc. (NASDAQ: BEAT) CEO Spotlighted in Interview on Making a Positive Social Impact

During interview, Vajdic recounts first steps of journey in the United States CEO points to key lessons he learned that helped him found HeartBeam The company has developed the first and only 3D-vector 12-lead electrocardiogram (“ECG”) platform for heart attack detection anytime, anywhere Growing up in Yugoslavia (now Serbia) as the only child of a well-known surgeon, HeartBeam (NASDAQ: BEAT) CEO and founder Branislav Vajdic, PhD, felt some pressure to study medicine and follow in his father’s footsteps. One day, at his father’s insistence, Vajdic observed a surgery — and fainted the moment he saw the first drop of blood.…

Continue Reading

BioMedWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 415.949.5050